430 related articles for article (PubMed ID: 17046984)
1. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
Burton S
J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
[TBL] [Abstract][Full Text] [Related]
2. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
3. Improving patient outcomes in schizophrenia: achieving remission.
Nasrallah HA; Lasser R
J Psychopharmacol; 2006 Nov; 20(6 Suppl):57-61. PubMed ID: 17046987
[TBL] [Abstract][Full Text] [Related]
4. Long-acting risperidone: focus on safety.
Möller HJ
Clin Ther; 2006 May; 28(5):633-51. PubMed ID: 16861087
[TBL] [Abstract][Full Text] [Related]
5. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
Kasper S
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
[TBL] [Abstract][Full Text] [Related]
6. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
Chue P
J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
[TBL] [Abstract][Full Text] [Related]
7. Partial compliance in schizophrenia and the impact on patient outcomes.
Llorca PM
Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience and management considerations with long-acting risperidone.
Parellada E
Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
[TBL] [Abstract][Full Text] [Related]
9. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
10. Subjective well-being and quality of life under atypical antipsychotic treatment.
Karow A; Naber D
Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610
[TBL] [Abstract][Full Text] [Related]
11. The effects of clozapine on cognitive functioning in schizophrenia.
McGurk SR
J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
[TBL] [Abstract][Full Text] [Related]
12. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
Faludi G
Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
[TBL] [Abstract][Full Text] [Related]
13. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
Naber D; Lambert M; Karow A
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
[TBL] [Abstract][Full Text] [Related]
14. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
[TBL] [Abstract][Full Text] [Related]
15. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
Velligan DI; Miller AL
J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
[TBL] [Abstract][Full Text] [Related]
16. The case for long-acting antipsychotic agents in the post-CATIE era.
Nasrallah HA
Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone and cognition: the evolving story.
Harvey PD
J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
[TBL] [Abstract][Full Text] [Related]
18. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
19. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
Bhanji NH; Chouinard G; Margolese HC
Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
[TBL] [Abstract][Full Text] [Related]
20. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
